Related Experiment Video

Updated: Mar 11, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K

Ratio of apoB/LDL: a potential clinical index for vascular cognitive impairment

Cheng Qian1, Fei Tan2

  • 1Department of Neurology, Shengjing hospital of China Medical University, NO.53 Huangxiang Road, Shenyang, China.

BMC Neurology
|November 27, 2016
PubMed

Insights

The ratio of apoprotein B (apoB) to low-density lipoprotein (LDL) may indicate vascular cognitive impairment (VCI) risk. Lower hyperlipidemia rates were observed in dementia patients with brain infarcts.

Area of Science:

  • Neurology
  • Cardiology
  • Gerontology

Background:

  • Vascular cognitive impairment (VCI) is linked to vascular disease and stroke.
  • Not all brain infarct patients develop VCI, suggesting unique risk factors.
  • Identifying these risk factors is crucial for understanding VCI progression.

Purpose of the Study:

  • To identify potential risk factors for VCI in patients with brain infarcts.
  • To compare risk factor prevalence between VCI patients and those with brain infarcts but no VCI.

Main Methods:

  • Study included 37 dementia patients and 74 brain infarction patients, all with basilar ganglia infarcts.
  • Compared frequencies of risk factors like age, hypertension, and hyperlipidemia between groups.

Main Results:

  • Hyperlipidemia incidence was significantly lower in dementia patients (35.14%) than infarction patients (59.46%).
  • A positive correlation was found between the apoB/LDL ratio and Mini Mental State Examination (MMSE) scores in the dementia group.

Conclusions:

  • The apoB/LDL ratio may serve as a potential clinical marker for VCI.
  • Further research is needed to validate apoB/LDL as a predictive index for VCI.
Abstract

Keywords:
Low density lipoproteinMMSEStrokeVascular cognitive impairmentVascular dementiaapoprotein B

More Related Videos

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.8K
Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

40.9K

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
678
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
541
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
790
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
569